Consistently, ghrelin has been shown to reduce inflammation and disease severity in numerous conditions, including sepsis, inflammatory bowel disease, arthritis, pancreatitis, obesity, autoimmune encephalomyelitis, and diabetic nephropathy [123,128,129,130]. Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.